Patient characteristics of the entire cohort and according to the ELN 2017 risk stratification
| . | All patients (861) . | ELN 2017 favorable (327) . | ELN 2017 intermediate (109) . | ELN 2017 adverse (245) . | ELN 2017 not classifiable (180) . | P* . |
|---|---|---|---|---|---|---|
| Age, years median (range) | 56 (17-76) | 54 (17-76) | 53 (20-75) | 58 (18-71) | 59 (17-71) | .33 |
| Sex, male n (%) | 449 (51) | 164 (50) | 48 (44) | 123 (50) | 107 (59) | .43 |
| WBC, median (range) (/109/L) | 9.88 (0.1-530) | 17.9 (0.6-361) | 45.6 (0.8-384.2) | 5.2 (0.4-313.6) | 3.4 (0.1-530) | <.001 |
| Hemoglobin, median (range) (g/L) | 89 (26-159) | 92 (34-150) | 91 (40-153) | 87 (38-159) | 87 (26-147) | .08 |
| Platelet count, median (range) (/109/L) | 62 (2-742) | 60 (5-453) | 62 (10-488) | 62 (6-465) | 74 (2-742) | .96 |
| PB blasts, median (range) (%) | 30 (0-100) | 37 (0-100) | 61 (0-100) | 20 (0-99) | 11 (0-98) | <.001 |
| BM blasts, median (range) (%) | 62 (1-100) | 66 (2-100) | 79 (17-100) | 57 (7-99) | 50 (9-99) | <.001 |
| NPM1 status | ||||||
| NPM1 mutated | 295 (34.3) | 217 (66.4) | 72 (66.1) | 6 | 0 | — |
| NPM1 unknown | 27 (3) | 5 (1.6) | 0 | 10 (9.2) | 12 (6.7) | — |
| FLT3-ITD status | ||||||
| FLT3-ITDlow | 60 (7.3) | 45 (13.8) | 2 (1.8) | 7 (2.9) | 6 (3.3) | — |
| FLT3-ITDhigh | 115 (13.4) | 6 (1.8) | 71 (65.1) | 38 (15.5) | 0 | — |
| FLT3-ITD unknown | 22 (2.6) | 3 (1) | 0 | 8 (3.7) | 11 (6.1) | — |
| MRC cytogenetic risk category16 | ||||||
| MRC favorable | 93 (10.8) | 93 (28.4) | 0 | 0 | 0 | — |
| MRC intermediate | 551 (64) | 215 (65.7) | 98 (91) | 80 (32.5) | 158 (87.8) | — |
| MRC adverse | 174 (20.2) | 2 (0.6) | 1 (1) | 161 (65.4) | 10 (5.5) | — |
| MRC not classifiable | 43 (5) | 17 (5.2) | 9 (8) | 5 (2.1) | 12 (6.7) | — |
| ELN-2010 risk stratification3 | ||||||
| Favorable | 255 (29.6) | 251 (76.8) | 1 (1) | 0 | 3 (1.7) | — |
| Intermediate I | 260 (30.2) | 38 (11.6) | 78 (71.5) | 44 (18) | 100 (55.5) | — |
| Intermediate II | 132 (15.3) | 28 (8.6) | 26 (23.8) | 19 (7.8) | 59 (32.8) | — |
| Adverse | 178 (20.7) | 1 (0.3) | 0 | 177 (72.2) | 0 | — |
| Not classifiable | 36 (4.21) | 9 (2.7) | 4 (3.7) | 5 (2) | 18 (10) | — |
| . | All patients (861) . | ELN 2017 favorable (327) . | ELN 2017 intermediate (109) . | ELN 2017 adverse (245) . | ELN 2017 not classifiable (180) . | P* . |
|---|---|---|---|---|---|---|
| Age, years median (range) | 56 (17-76) | 54 (17-76) | 53 (20-75) | 58 (18-71) | 59 (17-71) | .33 |
| Sex, male n (%) | 449 (51) | 164 (50) | 48 (44) | 123 (50) | 107 (59) | .43 |
| WBC, median (range) (/109/L) | 9.88 (0.1-530) | 17.9 (0.6-361) | 45.6 (0.8-384.2) | 5.2 (0.4-313.6) | 3.4 (0.1-530) | <.001 |
| Hemoglobin, median (range) (g/L) | 89 (26-159) | 92 (34-150) | 91 (40-153) | 87 (38-159) | 87 (26-147) | .08 |
| Platelet count, median (range) (/109/L) | 62 (2-742) | 60 (5-453) | 62 (10-488) | 62 (6-465) | 74 (2-742) | .96 |
| PB blasts, median (range) (%) | 30 (0-100) | 37 (0-100) | 61 (0-100) | 20 (0-99) | 11 (0-98) | <.001 |
| BM blasts, median (range) (%) | 62 (1-100) | 66 (2-100) | 79 (17-100) | 57 (7-99) | 50 (9-99) | <.001 |
| NPM1 status | ||||||
| NPM1 mutated | 295 (34.3) | 217 (66.4) | 72 (66.1) | 6 | 0 | — |
| NPM1 unknown | 27 (3) | 5 (1.6) | 0 | 10 (9.2) | 12 (6.7) | — |
| FLT3-ITD status | ||||||
| FLT3-ITDlow | 60 (7.3) | 45 (13.8) | 2 (1.8) | 7 (2.9) | 6 (3.3) | — |
| FLT3-ITDhigh | 115 (13.4) | 6 (1.8) | 71 (65.1) | 38 (15.5) | 0 | — |
| FLT3-ITD unknown | 22 (2.6) | 3 (1) | 0 | 8 (3.7) | 11 (6.1) | — |
| MRC cytogenetic risk category16 | ||||||
| MRC favorable | 93 (10.8) | 93 (28.4) | 0 | 0 | 0 | — |
| MRC intermediate | 551 (64) | 215 (65.7) | 98 (91) | 80 (32.5) | 158 (87.8) | — |
| MRC adverse | 174 (20.2) | 2 (0.6) | 1 (1) | 161 (65.4) | 10 (5.5) | — |
| MRC not classifiable | 43 (5) | 17 (5.2) | 9 (8) | 5 (2.1) | 12 (6.7) | — |
| ELN-2010 risk stratification3 | ||||||
| Favorable | 255 (29.6) | 251 (76.8) | 1 (1) | 0 | 3 (1.7) | — |
| Intermediate I | 260 (30.2) | 38 (11.6) | 78 (71.5) | 44 (18) | 100 (55.5) | — |
| Intermediate II | 132 (15.3) | 28 (8.6) | 26 (23.8) | 19 (7.8) | 59 (32.8) | — |
| Adverse | 178 (20.7) | 1 (0.3) | 0 | 177 (72.2) | 0 | — |
| Not classifiable | 36 (4.21) | 9 (2.7) | 4 (3.7) | 5 (2) | 18 (10) | — |
BM, bone marrow; PB, peripheral blood.
P value of the comparison among ELN 2017 classifiable patients.